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Abstract
Background: Drug resistant organisms pose an increasing threat to the successful treatment of common infections.
Understanding colonization patterns of these bacteria is important for effective antibiotic treatment and infection
control guidelines.
Methods: A prospective observational study was performed to determine the prevalence of colonization with
extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E), methicillin-resistant Staphylococcus aureus
(MRSA), and vancomycin-resistant Enterococcus (VRE) among patients admitted via the emergency department to a
public tertiary hospital in Singapore. Anterior nares, groin, axillary and rectal swabs were collected at admission and
cultured using standard bacteriological techniques. Clinical data including healthcare contact within the past
12 months and recent antibiotic use was collected and analyzed using a logistic regression model.
Results: 1006 patients were screened. 124 (12.4%) were colonized by ESBL-E, 18 (1.8%) by MRSA while no VRE was
detected. Antibiotic use within the past month was the only significant predictor for ESBL-E colonization in the
regression model, with an adjusted odds ratio (AOR) of 2.58 (1.04 to 6.42). In participants recently prescribed
antibiotics and hospitalized in the previous 3 months, 29.4% were colonized by ESBL-E. This represented 20.2% of
the total ESBL-E burden, and ESBL-E was also detected in 6.3% of participants with no healthcare contact.
Hospitalization and outpatient hospital visits predicted MRSA colonization in the univariate analysis. Neither was
statistically significant in the logistic regression model, with AORs for MRSA colonization following hospitalization in
the past 3 and 12 months of 3.81 [95% CI 0.84-17.28] and 3.48 [0.64-18.92] respectively.
Conclusion: A high prevalence of colonization with ESBL-E was evident among patients at admission, even in the
absence of recent antibiotic use or contact with healthcare.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus (VRE) emerged in
continental Asia following dissemination from Europe
and North America [1]. Over the past decade these
pathways have reversed, with Asia the probable source
of broad-spectrum β-lactamases such as CTX-M-15 and
NDM-1 [2,3]. Both are now identified globally.
VRE is relatively uncommonly identified in Asia,
while MRSA has become established in Asian hospitals
and is emerging in the community [4]. Extended-spectrum
β-lactamase-producing Enterobacteriaceae (ESBL-E) have
reached an extraordinary prevalence in clinical isolates
from both hospitals and the community. Surveillance
by the Study for Monitoring Antimicrobial Trends
(SMART) in the Asia-Pacific region from 2008–2010
detected ESBL-E in 32.8% of urinary tract infections
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and 11.2% of intra-abdominal infections (IAI) [5,6].
Almost 20% of ESBL-E were cultured from community-
onset IAI. ESBL-E fecal carriage rates among healthy
volunteers in Asia have ranged from 6.4% in Japan to
an extraordinary 61.7% in rural Thailand [7,8].
As many bacterial infections derive from host flora,
colonization by drug resistant organisms is a risk for
drug resistant infections [9,10]. An increased mortality
with these infections correlates with delayed recognition
and inadequate empirical therapy [11,12]. Knowledge of
local resistance patterns is therefore important for
evidence-based institutional empiric antibiotic treatment
and infection control guidelines. We developed a pro-
spective study to determine the prevalence of colonization
by ESBL-E, MRSA and VRE in patients admitted to our




We conducted this prospective observational study at
the emergency department (ED) of Tan Tock Seng
Hospital, Singapore. This is a public tertiary hospital of
more than 1500 inpatient beds and a busy ED with more
than 11,000 attendances and almost 4000 admissions per
month in 2006.
Consecutive patients over 16 years of age planned for
hospital admission were approached to participate. The
recruitment period was 12-8 pm Monday to Friday from
November 2006 to February 2007. Pregnant women
were excluded. Target recruitment was 1000, calculated
to estimate the colonization rate for MRSA with 95%
confidence within 1% of its actual value, based on an ex-
pected value of 2% from previous institutional surveil-
lance studies.
Anterior nares, groin, axilla and rectum were swabbed
by a research nurse in the ED. If the participant declined
or was unsuitable for rectal swabbing, freshly passed
stools were collected within 24 hours of admission. Clin-
ical data recorded at admission from the participant or
next-of-kin included age, gender, co-morbidities, resi-
dence in a care facility, hospitalization or outpatient
(hospital and primary care) healthcare contact within
the last 12 months and receipt of antibiotics in the last
3 months.
Written informed consent was obtained from all par-
ticipants or the next-of-kin and the study was approved
by the Institutional Ethics Committee (the National
Healthcare Group Domain Specific Review Board).
Bacteria identification and resistance testing
Rectal swabs/stool specimens were inoculated onto two
MacConkey agar plates supplemented with 1 mg/L of ei-
ther cefotaxime or ceftazidime and incubated for 48 hours.
Enterobacteriaceae were identified by Microbact 12A
(Oxoid, UK) and the presence of ESBL screened with
double-disc synergy using cefotaxime 30 μg and ceftazi-
dime 30 μg discs placed 25 mm from an amoxicillin-
clavulanate (20 μg-10 μg) disc. Isolates screening positive
for ESBL were tested with a multiplex PCR assay for de-
tection of CTX-M clusters, according to published proto-
cols [13].
Nares, groin and axillary swabs were inoculated onto
mannitol salt agar supplemented with oxacillin 6 μg/ml
and incubated for 48 hours. MRSA was identified by
gram stain, tube coagulase test and antimicrobial suscep-
tibility testing.
Rectal swabs/stool specimens were also inoculated
onto bile-esculin-azide agar containing 6 mgs/L vanco-
mycin for 48 hours and black colonies identified as en-
terococci by conventional methods including motility
and pigment production. Vancomycin resistance was
confirmed using vancomycin minimum concentration
(MIC) E-test (AB BioDisk, Sweden) and an in-house van
gene polymerase chain reaction (PCR).
Disc diffusion anti-microbial susceptibility testing was
performed for all isolates in accordance with the 2007
Clinical Laboratory Standard Institute Guidelines [14].
Data analysis
An initial exploratory analysis was performed with Fisher’s
exact test. Logistic regression was used to determine
which covariates were significantly associated with the de-
tection of ESBL-E, MRSA or VRE. All identified covariates
were entered into the model before employing a backward
elimination algorithm. Goodness-of-fit was estimated with
the Hosmer Lemeshow (H-L) test. The sensitivity and spe-
cificity of individual measures for predicting colonization
was estimated using the efficient-score method.
Participants who reported no contact with healthcare,
healthcare workers, antibiotics or nursing homes were
used as a surrogate for the community prevalence of
colonization by ESBL-E, MRSA or VRE.
Statistical analyses were performed using Stata 12.0
(Stata Corporation, U.S.A.). All statistical tests were con-
ducted at a two-sided 5% level of significance.
Results
1006 out of 1592 patients (63.2%) admitted during the re-
cruitment period consented to participate. Rectal swabs
were obtained from 1001 (99.5%); 3 (0.3%) provided stool
specimens; 2 (0.2%) did not provide any sample. MRSA
screening was performed on all 1006.
Baseline characteristics and findings are summarized
in Table 1. 124 (12.4%) were colonized by ESBL-E, 18
(1.8%) by MRSA, and no VRE was detected.
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Table 1 Sample characteristics and univariate analysis
MRSA No (n = 988) Yes (n = 18) p-value ESBL-E No (n = 880) Yes (n = 124) p-value
Demographics:
Gender
Male 643 (98.2%) 12 (1.8%) NS 571 (87.2%) 84 (12.8%) NS
Female 345 (98.3%) 6 (1.7%) 309 (88.5%) 40 (11.5%)
Ethnicity
Chinese 639 (97.6%) 16 (2.4%) NS 571 (87.2%) 84 (12.8%) NS
Malay 166 (99.4%) 1 (0.6%) 149 (89.2%) 18 (10.8%)
Indian 133 (99.2%) 1 (0.8%) 115 (86.5%) 18 (13.5%)
Others 50 (100.0%) 0 (0.0%) 45 (91.8%) 4 (8.2%)
Residence in Nursing Home
No 966 (98.2%) 18 (1.8%) NS 860 (87.6%) 122 (12.4%) NS
Yes 22 (100.0%) 0 (0.0%) 20 (90.9%) 2 (9.1%)
Comorbid conditions:
Diabetes Mellitus
No 782 (98.7%) 10 (1.3%) 0.035 697 (88.2%) 93 (11.8%) NS
Yes 206 (96.3%) 8 (3.7%) 183 (85.5%) 31 (11.5%)
ESRF
No 977 (98.2%) 18 (1.8%) NS 869 (87.5%) 124 (12.5%) NS
Yes 11 (100.0%) 0 (0.0%) 11 (100.0%) 0 (0.0%)
Liver Cirrhosis
No 977 (98.2%) 18 (1.8%) NS 869 (87.5%) 124 (12.5%) NS
Yes 11 (100.0%) 0 (0.0%) 11 (100.0%) 0 (0.0%)
Cancer
No 962 (98.2%) 18 (1.8%) NS 854 (87.3%) 124 (12.7%) NS
Yes 26 (100.0%) 0 (100.0%) 26 (100.0%) 0 (0.0%)
HIV
No 985 (98.2%) 18 (1.8%) NS 878 (87.7%) 123 (12.3%) NS
Yes 3 (100.0%) 0 (0.0%) 2 (66.7%) 1 (33.3%)
Corticosteroids
No 944 (98.2%) 17 (1.8%) NS 845 (88.1%) 114 (11.9%) NS
Yes 43 (97.7%) 1 (2.3%) 34 (77.3%) 10 (22.7%)
Healthcare risk factors:
Hospitalization
Within 3 month 155 (93.4%) 11 (6.6%) <0.001 131 (78.9%) 35 (21.1%) <0.001
Within 12 month 297 (95.5%) 14 (4.5%) <0.001 257 (82.6%) 54 (17.4%) 0.002
Oral antibiotics
Within 1 month 279 (97.2%) 8 (2.8%) NS 227 (79.1%) 60 (20.9%) <0.001
Within 3 month 343 (97.4%) 9 (2.6%) NS 286 (81.3%) 66 (18.7%) <0.001
Outpatient hospital visit
Within 3 month 402 (96.9%) 13 (3.1%) 0.013 347 (83.8%) 67 (16.2%) 0.002
Within 12 month 536 (97.3%) 15 (2.7%) 0.016 470 (85.4%) 80 (14.6%) 0.021
Primary care visit
Within 3 month 657 (97.6%) 16 (2.4%) 0.046 584 (87.0%) 87 (13.0%) NS
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Univariate analysis and logistic regression
Inpatient or outpatient hospital care and recent anti-
biotic prescription were significant risk factors for ESBL-
E colonization in the univariate analysis (Table 1). In the
logit model only antibiotic use within 1 month prior to
admission significantly predicted ESBL-E colonization,
with an AOR of 2.58 [1.04 to 6.42] (Table 2).
For MRSA colonization, inpatient or outpatient hospital
care within the previous 3 or 12 months were significantly
associated in the univariate analysis (Table 1). Neither
factor was statistically significant in the logit model. Ad-
justed odds ratios (AOR) for MRSA colonization following
hospitalization in the past 3 and 12 months were 3.81
[95% CI 0.84-17.28] and 3.48 [0.64-18.92] respectively
(Table 2).
Both logit models provided a satisfactory fit to the data
(H-L test: ESBL-E p-value = 0.52, MRSA p-value = 0.87).
Community colonization
95 participants reported no contact with healthcare,
healthcare workers, antibiotics or nursing homes; 6
(6.3%) were colonized by ESBL-E, 0 by MRSA and 0 by
VRE.
The importance of recent antibiotic use for ESBL-E
colonization was evident from a comparison of colonization
rates in participants stratified by attendance at different
levels of the healthcare system in the previous three
months, and antibiotic use in the previous month (Table 3).
Baseline colonization prevalence in each subgroup was not
significantly different from the putative community preva-
lence of 6.3% (Fisher’s exact test), however prevalence was
significantly higher than baseline if antibiotics were admin-
istered in the previous month. In participants who had been
recently admitted to hospital and received antibiotics,
29.4% were colonized by ESBL-E.
Predicting colonization
Oral antibiotics in the past month predicted ESBL-E fecal
carriage with a sensitivity of 48.4% [95% CI 39.4–57.5%]
and specificity of 74.2% [71.2–77.0%]. Specificity could be
improved by filtering for additional hospitalization in
the past 3 months, but with a significant loss of sensi-
tivity: this was 22.1% [15.3-28.2%] sensitive and 89.4%
[87.0-91.3%] specific. Specificity was improved further
by combining oral antibiotics in the past month and
hospitalization within the past 3 months. This predicted
ESBL-E fecal carriage with 20.2% [13.7–28.5%] sensitiv-
ity and 93.2% [91.3-94.7%] specificity.
Hospitalization within the last 3 months was 61.1%
[95% CI 36.1-81.7%] sensitive and 84% [81.9-86.5%] spe-
cific for MRSA colonization. Sensitivity could be im-
proved to 77.8% [51.9-92.6%], but with a specificity of
Table 1 Sample characteristics and univariate analysis (Continued)
Within 12 month 729 (97.9%) 16 (2.1%) NS 652 (87.8%) 91 (12.2%) NS
HCW contact
No 853 (98.3%) 15 (1.7%) NS 759 (87.5%) 108 (12.5%) NS
Yes 135 (97.8%) 3 (2.2%) 121 (88.3%) 16 (11.7%)
ESRF: End-stage Renal Failure; HIV: Human Immunodeficiency Virus; HCW: Healthcare Worker.
Table 2 Multiple logistic regression analyses of MRSA and ESBL-E colonization risk factors
Featured covariates* MRSA AOR 95% C.I. ESBL-E AOR 95% C.I.
Hospitalization
Within 3 month 3.81 0.84 to 17.28 1.38 0.71 to 2.69
Within 12 month 3.48 0.64 to 18.92 1.35 0.73 to 2.48
Use of oral antibiotics
Within 1 month 1.57 0.17 to 14.43 2.58** 1.04 to 6.42
Within 3 month 0.67 0.08 to 6.78 0.94 0.38 to 2.36
Outpatient visit
Within 3 month 0.97 0.17 to 5.64 1.36 0.69 to 2.69
Within 12 month 1.43 0.18 to 11.13 0.89 0.43 to 1.80
Primary care visit
Within 3 month Not estimated Not estimated 2.08 0.72 to 6.01
Within 12 month Not estimated Not estimated 0.41 0.14 to 1.24
Contact with Healthcare Worker 1.30 0.32 to 5.33 0.86 0.47 to 1.57
*The models are adjusted for demographics and co-morbid conditions.
**Statistically significant at 5%.
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69% [70.0-72.8%] using hospitalization in the past
12 months to predict MRSA colonization.
Extended spectrum β-lactamases
133 Enterobacteriaceae isolates from 124 participants
tested positive for ESBL production by double disc synergy.
71% of these were E.coli and 19%K.pneumoniae. 99
(74.4%) were PCR positive for at least one CTX-M enzyme,
predominantly cluster 1 (64 isolates, 65%) or 9 (32 isolates,
24%). 3 isolates produced both cluster 1 and 9 CTX-M.
Discussion
Ceftriaxone resistance among clinical isolates of E.coli and
K.pneumoniae from public hospitals in Singapore has
reached 20-30% [15]. This incidence is rising and corre-
lates with increasing prescription of broad spectrum anti-
biotics. We identified a similar high burden of ESBL-E
colonization from rectal swab cultures. ESBL-E was de-
tected in 29.4% of subjects who had been recently hospi-
talized and were recipients of antibiotics. 6.3% of subjects
without healthcare contact or antibiotics were detected as
ESBL-E colonized. The source of these organisms is of
major concern.
In ESBL-E high prevalence countries such as Singapore,
nosocomial transmission may not be the most important
acquisition route. A study in a Swiss hospital with low
ESBL-E prevalence observed infrequent transmission
events even without contact isolation [16]. Modeling
ESBL-E colonization in a French pediatric unit described
the success of contact isolation in preventing nosocomial
transmission, but its overall ineffectiveness due to the high
incidence of sporadic cases from the community [17]. A
similar finding from a study of ESBL-E transmission dy-
namics in Switzerland, detected more inpatient ESBL-E
fecal carriage acquired from the community than in
hospital [18]. Transmission between household mem-
bers was also more frequent than between patients,
though it was not clear if it was acquired from a com-
mon source – presumed to be food – or person-to-
person.
The importance of recent antibiotic use in this study
suggests that host susceptibility to colonization is a crit-
ical factor. Acquisition of ESBL-E from community or
nosocomial sources may be facilitated by disrupting the
host gut microbiome and providing a selective advantage
for antibiotic-resistant organisms. Given the high rate of
colonization in patients with no identified risk factors,
an alternative hypothesis is that antibiotic use selects for
ESBL-E from host indigenous gut flora, increasing the
colonization burden. The sensitivity of rectal swabs for
detection of ESBL-E has not been widely investigated, but
was reported to correlate with density of colonization [19].
Antibiotics also generate de novo ESBL-E, by promoting
DNA recombination events between gut bacteria [20].
Travel to Asia has been identified as a risk factor for
ESBL-E fecal carriage in European and Australian pro-
spective cohorts [21,22]. In both these studies, acquisi-
tion was associated with traveler’s diarrhea, but not
dependent on antibiotic use or healthcare contact. Curi-
ously this is despite the isolation of ESBL-E from more
than 90% of retail chicken meat in separate European
studies [23,24]. This disconnect could be due to environ-
mental or diet differences facilitating ESBL-E acquisition
in Asia, or microbiome changes as a result of travel itself
increasing susceptibility to colonization by antibiotic-
resistant bacteria. CTX-M production by E.coli carried
on chicken, pigs and cattle in China has been reported,
and a systematic study of agricultural, food and clinical
ESBL-E isolates in Asia would be interesting [25].
MRSA is a common healthcare-associated pathogen in
Singapore. A colonization prevalence of 41% has been
reported from nursing homes residents admitted to a pub-
lic acute care hospital, and 6% among all medical and sur-
gical admissions [26]. Community-acquired MRSA strains
are infrequently recognized as a cause of infections in
Singapore, and its contribution to community MRSA
colonization is not known [27].
Transmission of MRSA from colonized hands and en-
vironmental surfaces to new hosts is well established
[28,29]. The high AOR in the logit model between
Table 3 ESBL-E fecal colonization by healthcare contact in the past three months and antibiotic use in the previous
month
Sub-group Number of participants Prevalence Odds ratio
(95% C.I.)
p-value
ESBL-E colonized Not colonized
No healthcare contact or antibiotics 6 95 6.3%
Primary care, no antibiotics 36 452 8.0% 2.90* (1.84 to 4.57) <0.0001
Primary care and antibiotics 51 221 23.1%
Outpatient, no antibiotics 24 245 9.8% 1.78* (1.05 to 3.02) 0.033
Outpatient and antibiotics 43 247 17.4%
Hospitalization, no antibiotics 10 81 12.3% 2.38* (1.08 to 5.02) 0.032
Hospitalization and antibiotics 25 85 29.4%
*Statistically significant at 5%.
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hospitalization and MRSA colonization is consistent
with this as a clinically significant factor. Antibiotic use
has also been associated with colonization and infection
by MRSA. Failure to identify this here may be due to the
small number of cases [30,31]. Failure to isolate VRE
was not unexpected, as the prevalence in Singapore is
low outside of nosocomial outbreaks [32].
This study has a number of limitations. Accurate clin-
ical data was dependent on recall by study participants
or next-of-kin and was not independently verified by
medical records. Data was not collected on antibiotic
type and duration or frequency of prior contact with
healthcare institutions as this was judged unreliable from
patient recall. Our ability to analyze risk factors for
colonization by MRSA and VRE was limited by the
study design, due to the low detected prevalence. A case
control study would help elaborate these.
Acquisition rates in hospital were not investigated, and
this could have provided additional evidence to refine
our conclusions. More accurate methods for detecting
MRSA, ESBL-E and VRE colonization are now available:
for example PCR-based detection methods may be more
accurate and sensitive [33]. We were also unable to per-
form ESBL genotyping or bacterial strain typing, to de-
termine if CTX-M-15 was the major enzyme in clusters
1 and 9, or if ESBL-E strains differed between apparent
community- and hospital-acquired isolates. The prevalence
of resistance mechanisms such as carbapenemases which
have become of increasing concern was not assessed.
Conclusions
ESBL-E colonization was detected with high prevalence
in subjects who were recently hospitalized and received
antibiotics. Identifying subjects who were colonized by
ESBL-E accurately was difficult using just the clinical
data collected. Not least this was due to the significant
proportion of ESBL-E associated with limited healthcare
contact. Identifying the source of these organisms and
the relative contributions of community and nosocomial
transmission may be important for understanding how
to control their spread.
Abbreviations
AOR: Adjusted odds ratio; CI: Confidence interval; ED: Emergency department;
ESBL-E: Extended-Spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E);
ESRF: End-stage renal failure; HCW: Healthcare worker; HIV: Human
immunodeficiency virus; H-L: Hosmer Lemeshow; IAI: Intra-abdominal infection;
OR: Odds ratio; PCR: Polymerase chain reaction; MRSA: Methicillin-resistant
Staphylococcus aureus; VRE: Vancomycin-resistant Enterococcus.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BY collected and analyzed data, and drafted the manuscript; PK conceived
and designed the study, and performed culture and susceptibility testing; SC
analyzed data and helped draft the manuscript; DL conceived and designed
the study, collected and analyzed data and helped draft the manuscript; LY
conceived and designed the study. All authors read and approved the final
manuscript.
Acknowledgments
The study was funded by a Health Quality Improvement Fund grant from
the Ministry of Health, Singapore. BY is supported by the National Healthcare
Group Clinician Scientist Career Scheme.
Author details
1Institute of Infectious Diseases and Epidemiology, Communicable Diseases
Centre, Singapore, Singapore. 2Department of Medicine, National University
of Singapore, Singapore, Singapore. 3Department of Laboratory Medicine,
Tan Tock Seng Hospital, Singapore, Singapore. 4Department of Mathematics
& Statistics, La Trobe University, Melbourne, Australia.
Received: 19 September 2013 Accepted: 28 May 2014
Published: 2 June 2014
References
1. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA: The global spread of
healthcare-associated multidrug-resistant bacteria: a perspective from
Asia. Clin Infect Dis: an official publication of the Infectious Diseases Society of
America 2013, 56(9):1310–1318.
2. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R,
Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan
S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray
U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S,
Warner M, Welfare W, Livermore DM, et al: Emergence of a new antibiotic
resistance mechanism in India, Pakistan, and the UK: a molecular,
biological, and epidemiological study. Lancet Infect Dis 2010, 10(9):597–602.
3. Karim A, Poirel L, Nagarajan S, Nordmann P: Plasmid-mediated extended-
spectrum beta-lactamase (CTX-M-3 like) from India and gene association
with insertion sequence ISEcp1. FEMS Microbiol Lett 2001, 201(2):237–241.
4. Song JH, Hsueh PR, Chung DR, Ko KS, Kang CI, Peck KR, Yeom JS, Kim SW,
Chang HH, Kim YS, Jung SI, Son JS, So TM, Lalitha MK, Yang Y, Huang SG,
Wang H, Lu Q, Carlos CC, Perera JA, Chiu CH, Liu JW, Chongthaleong A,
Thamlikitkul V, Van PH, ANSORP Study Group: Spread of methicillin-
resistant Staphylococcus aureus between the community and the
hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother
2011, 66(5):1061–1069.
5. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, Huang CC, Liu CE, Ko WC,
Wang JH, Tang HJ, Yu KW, Chen YS, Chuang YC, Xu Y, Ni Y, Chen YH, Hsueh
PR: Epidemiology and antimicrobial susceptibility profiles of Gram-
negative bacteria causing urinary tract infections in the Asia-Pacific
region: 2009–2010 results from the Study for Monitoring Antimicrobial
Resistance Trends (SMART). Int J Antimicrob Agents 2012, 40(Suppl):S37–S43.
6. Sheng WH, Badal RE, Hsueh PR: Distribution of extended-spectrum beta-
lactamases, AmpC beta-lactamases, and carbapenemases among
Enterobacteriaceae isolates causing intra-abdominal infections in the
Asia-Pacific region: results of the study for Monitoring Antimicrobial
Resistance Trends (SMART). Antimicrob Agents Chemother 2013,
57(7):2981–2988.
7. Luvsansharav UO, Hirai I, Niki M, Nakata A, Yoshinaga A, Moriyama T,
Yamamoto Y: Prevalence of fecal carriage of extended-spectrum beta-
lactamase-producing Enterobacteriaceae among healthy adult people in
Japan. J Infect Chemotherapy: official journal of the Japan Society of
Chemotherapy 2011, 17(5):722–725.
8. Sasaki T, Hirai I, Niki M, Nakamura T, Komalamisra C, Maipanich W, Kusolsuk
T, Sa-Nguankiat S, Pubampen S, Yamamoto Y: High prevalence of CTX-M
beta-lactamase-producing Enterobacteriaceae in stool specimens
obtained from healthy individuals in Thailand. J Antimicrob Chemother
2010, 65(4):666–668.
9. Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, Noskin GA,
Zembower T: Screening for extended-spectrum beta-lactamase-
producing Enterobacteriaceae among high-risk patients and rates of
subsequent bacteremia. Clin Infect Dis: an official publication of the
Infectious Diseases Society of America 2007, 45(7):846–852.
10. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR: Methicillin-
resistant Staphylococcus aureus (MRSA) nares colonization at hospital
admission and its effect on subsequent MRSA infection. Clin Infect Dis: an
Young et al. BMC Infectious Diseases 2014, 14:298 Page 6 of 7
http://www.biomedcentral.com/1471-2334/14/298
official publication of the Infectious Diseases Society of America 2004,
39(6):776–782.
11. Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy
associated with extended-spectrum beta-lactamase production in
Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
J Antimicrob Chemother 2007, 60(5):913–920.
12. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ: Outcomes analysis of
delayed antibiotic treatment for hospital-acquired Staphylococcus
aureus bacteremia. Clin Infect Dis: an official publication of the Infectious
Diseases Society of America 2003, 36(11):1418–1423.
13. Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R:
Dramatic increase in prevalence of fecal carriage of extended-spectrum
beta-lactamase-producing Enterobacteriaceae during nonoutbreak
situations in Spain. J Clin Microbiol 2004, 42(10):4769–4775.
14. CLSI: Performance Standards for Antimicrobial Susceptibility Testing;
Seventeenth Informational Supplement. CLSI document M100-S17.
Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2007.
15. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH: Surveillance and
correlation of antibiotic prescription and resistance of Gram-negative
bacteria in Singaporean hospitals. Antimicrob Agents Chemother 2010,
54(3):1173–1178.
16. Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF: Rate of
transmission of extended-spectrum beta-lactamase-producing entero-
bacteriaceae without contact isolation. Clin Infect Dis: an official publication
of the Infectious Diseases Society of America 2012, 55(11):1505–1511.
17. Domenech de Celles M, Zahar JR, Abadie V, Guillemot D: Limits of patient
isolation measures to control extended-spectrum beta-lactamase-
producing Enterobacteriaceae: model-based analysis of clinical data in a
pediatric ward. BMC Infect Dis 2013, 13:187.
18. Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, Kronenberg
A, Rohrer C, Aebi S, Endimiani A, Droz S, Mühlemann K: Transmission dynamics
of extended-spectrum beta-lactamase-producing Enterobacteriaceae
in the tertiary care hospital and the household setting. Clin Infect Dis: an
official publication of the Infectious Diseases Society of America 2012, 55(7):967–975.
19. Lautenbach E, Harris AD, Perencevich EN, Nachamkin I, Tolomeo P, Metlay
JP: Test characteristics of perirectal and rectal swab compared to stool
sample for detection of fluoroquinolone-resistant Escherichia coli in the
gastrointestinal tract. Antimicrob Agents Chemother 2005, 49(2):798–800.
20. Modi SR, Lee HH, Spina CS, Collins JJ: Antibiotic treatment expands the
resistance reservoir and ecological network of the phage metagenome.
Nature 2013, 499(7457):219–222.
21. Tangden T, Cars O, Melhus A, Lowdin E: Foreign travel is a major risk
factor for colonization with Escherichia coli producing CTX-M-type
extended-spectrum beta-lactamases: a prospective study with Swedish
volunteers. Antimicrob Agents Chemother 2010, 54(9):3564–3568.
22. Kennedy K, Collignon P: Colonisation with Escherichia coli resistant to
“critically important” antibiotics: a high risk for international travellers.
Eur J Clin Microbiol Infect Dis: official publication of the European Society of
Clinical Microbiology 2010, 29(12):1501–1506.
23. Egea P, Lopez-Cerero L, Torres E, Gomez-Sanchez Mdel C, Serrano L, Navarro
Sanchez-Ortiz MD, Rodriguez-Bano J, Pascual A: Increased raw poultry
meat colonization by extended spectrum beta-lactamase-producing
Escherichia coli in the south of Spain. Int J Food Microbiol 2012,
159(2):69–73.
24. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, Voets GM, van den
Munckhof MP, van Essen-Zandbergen A, Platteel T, Fluit AC, van de Sande-
Bruinsma N, Scharinga J, Bonten MJ, Mevius DJ, National ESBL surveillance
group: Dutch patients, retail chicken meat and poultry share the same
ESBL genes, plasmids and strains. Clin Microbiol Infect: the official publication
of the European Society of Clinical Microbiology and Infectious Diseases 2011,
17(6):873–880.
25. Zheng H, Zeng Z, Chen S, Liu Y, Yao Q, Deng Y, Chen X, Lv L, Zhuo C, Chen
Z, Liu JH: Prevalence and characterisation of CTX-M beta-lactamases
amongst Escherichia coli isolates from healthy food animals in China.
Int J Antimicrob Agents 2012, 39(4):305–310.
26. Verrall A, Merchant R, Dillon J, Ying D, Fisher D: Impact of nursing home
residence on hospital epidemiology of meticillin-resistant Staphylococcus
aureus: a perspective from Asia. J Hosp Infect 2013, 83(3):250–252.
27. Hsu LY, Koh YL, Chlebicka NL, Tan TY, Krishnan P, Lin RT, Tee N, Barkham T,
Koh TH: Establishment of ST30 as the predominant clonal type among
community-associated methicillin-resistant Staphylococcus aureus
isolates in Singapore. J Clin Microbiol 2006, 44(3):1090–1093.
28. Coello R, Jimenez J, Garcia M, Arroyo P, Minguez D, Fernandez C, Cruzet F,
Gaspar C: Prospective study of infection, colonization and carriage of
methicillin-resistant Staphylococcus aureus in an outbreak affecting 990
patients. Eur J Clin Microbiol Infect Dis: official publication of the European
Society of Clinical Microbiology 1994, 13(1):74–81.
29. Boyce JM, Potter-Bynoe G, Chenevert C, King T: Environmental contamination
due to methicillin-resistant Staphylococcus aureus: possible infection
control implications. Infect Control Hosp Epidemiol: the official journal of the
Society of Hospital Epidemiologists of America 1997, 18(9):622–627.
30. Hill DA, Herford T, Parratt D: Antibiotic usage and methicillin-resistant
Staphylococcus aureus: an analysis of causality. J Antimicrob Chemother
1998, 42(5):676–677.
31. Graffunder EM, Venezia RA: Risk factors associated with nosocomial
methicillin-resistant Staphylococcus aureus (MRSA) infection including
previous use of antimicrobials. J Antimicrob Chemother 2002, 49(6):999–1005.
32. Cai Y, Chan JP, Fisher DA, Hsu LY, Koh TH, Krishnan P, Kwa AL, Tan TY, Tee
NW: Vancomycin-resistant Enterococci in Singaporean hospitals: 5-year
results of a multi-centre surveillance programme. Ann Acad Med Singap
2012, 41(2):77–81.
33. Win MK, Yung CF, Poh BF, Krishnan PU, Seet SK, Leo YS, Ang B: Evaluation
of universal methicillin-resistant Staphylococcus aureus screening using
nasal polymerase chain reaction compared with nasal, axilla, and groin
and throat and perianal cultures in a hospital setting. Infect Control Hosp
Epidemiol: the official journal of the Society of Hospital Epidemiologists of
America 2013, 34(12):1335–1337.
doi:10.1186/1471-2334-14-298
Cite this article as: Young et al.: A prospective observational study of
the prevalence and risk factors for colonization by antibiotic resistant
bacteria in patients at admission to hospital in Singapore. BMC Infectious
Diseases 2014 14:298.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Young et al. BMC Infectious Diseases 2014, 14:298 Page 7 of 7
http://www.biomedcentral.com/1471-2334/14/298
